Repligen Corp
RGEN118.100USD
-3.230-2.66%
Handelsschluss 07/15, 16:00（ET）Kurse um 15 Minuten verzögert
6.63BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Repligen Corp Unternehmen
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Unternehmensinformationen
BörsenkürzelRGEN
Name des UnternehmensRepligen Corp
IPO-datumApr 29, 1986
Gegründet am1981
CEOMr. Olivier Loeillot
Anzahl der mitarbeiter1778
WertpapierartOrdinary Share
GeschäftsjahresendeApr 29
AddresseBuilding 1, Suite 100
StadtWALTHAM
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02453
Telefon17814499560
Websitehttps://www.repligen.com/
BörsenkürzelRGEN
IPO-datumApr 29, 1986
Gegründet am1981
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.82K
-47.79%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jason K. Garland
Mr. Jason K. Garland
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
91.29K
+1.08%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
32.55K
+3.08%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
16.82K
-47.79%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
12.56K
+147.18%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
4.94K
+24.53%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
3.32K
+41.49%
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
North America
84.59M
50.00%
Europe
59.21M
35.00%
APAC/Other
25.38M
15.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, May 18
Aktualisiert: Sun, May 18
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
T. Rowe Price Associates, Inc.
13.38%
The Vanguard Group, Inc.
9.02%
BlackRock Institutional Trust Company, N.A.
8.70%
Roy T. Eddleman UEO
5.89%
State Street Global Advisors (US)
3.01%
Other
60.00%
Aktionäre
Aktionäre
Anteil
T. Rowe Price Associates, Inc.
13.38%
The Vanguard Group, Inc.
9.02%
BlackRock Institutional Trust Company, N.A.
8.70%
Roy T. Eddleman UEO
5.89%
State Street Global Advisors (US)
3.01%
Other
60.00%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
53.24%
Investment Advisor/Hedge Fund
36.52%
Hedge Fund
9.08%
Individual Investor
6.40%
Pension Fund
2.44%
Research Firm
1.88%
Bank and Trust
0.70%
Family Office
0.52%
Family Office
0.50%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
1017
62.55M
111.32%
-2.87M
2025Q1
1054
62.91M
111.98%
-2.72M
2024Q4
1054
61.13M
109.11%
-3.76M
2024Q3
1046
60.75M
108.48%
-6.10M
2024Q2
1039
61.28M
109.67%
-2.73M
2024Q1
1036
60.56M
108.45%
-5.41M
2023Q4
1062
62.13M
111.29%
-2.30M
2023Q3
1063
61.47M
110.27%
+2.91M
2023Q2
1050
59.01M
105.99%
+1.34M
2023Q1
1061
58.23M
104.67%
+1.01M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
T. Rowe Price Associates, Inc.
7.52M
13.38%
+427.74K
+6.03%
Mar 31, 2025
The Vanguard Group, Inc.
5.07M
9.02%
-21.20K
-0.42%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.89M
8.7%
+13.96K
+0.29%
Mar 31, 2025
Roy T. Eddleman UEO
3.31M
5.89%
-67.50K
-2.00%
Dec 31, 2024
State Street Global Advisors (US)
1.69M
3.01%
-2.27K
-0.13%
Mar 31, 2025
Invesco Advisers, Inc.
1.60M
2.84%
+768.85K
+93.02%
Mar 31, 2025
Champlain Investment Partners, LLC
1.46M
2.61%
-79.53K
-5.15%
Mar 31, 2025
Citadel Advisors LLC
1.33M
2.37%
+150.23K
+12.74%
Mar 31, 2025
Sands Capital Management, LLC
1.29M
2.3%
-70.06K
-5.14%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.22M
2.17%
-37.63K
-2.99%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sun, Jul 6
Aktualisiert: Sun, Jul 6
Name
Anteil
Alger Mid Cap 40 ETF
4.53%
First Trust NYSE Arca Biotechnology Index Fund
3.02%
BNY Mellon Innovators ETF
2.82%
iShares Health Innovation Active ETF
1.58%
Congress SMid Growth ETF
1.36%
VanEck Biotech ETF
1.33%
Franklin Genomic Advancements ETF
1.27%
WisdomTree BioRevolution Fund
0.97%
Pacer US Export Leaders ETF
0.77%
iShares Biotechnology ETF
0.66%
Mehr Anzeigen
Alger Mid Cap 40 ETF
Anteil4.53%
First Trust NYSE Arca Biotechnology Index Fund
Anteil3.02%
BNY Mellon Innovators ETF
Anteil2.82%
iShares Health Innovation Active ETF
Anteil1.58%
Congress SMid Growth ETF
Anteil1.36%
VanEck Biotech ETF
Anteil1.33%
Franklin Genomic Advancements ETF
Anteil1.27%
WisdomTree BioRevolution Fund
Anteil0.97%
Pacer US Export Leaders ETF
Anteil0.77%
iShares Biotechnology ETF
Anteil0.66%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
